session 5
DESCRIPTION
Session 5. Case. Diagnosis - Sclerosing adenosis with lobular neoplasia. No invasion in images provided. Update - Risk with LISN. Meta-analysis 9 studies of 228 patients 15% ipsilateral, 9% contralateral carcinoma Ipsilateral 3x more likely than contralateral. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/1.jpg)
Session 5
![Page 2: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/2.jpg)
Case
![Page 3: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/3.jpg)
![Page 4: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/4.jpg)
![Page 5: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/5.jpg)
![Page 6: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/6.jpg)
![Page 7: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/7.jpg)
![Page 8: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/8.jpg)
![Page 9: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/9.jpg)
![Page 10: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/10.jpg)
![Page 11: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/11.jpg)
![Page 12: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/12.jpg)
![Page 13: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/13.jpg)
![Page 14: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/14.jpg)
Diagnosis - Sclerosing adenosis with
lobular neoplasia.
No invasion in images provided.
![Page 15: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/15.jpg)
![Page 16: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/16.jpg)
![Page 17: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/17.jpg)
Update - Risk with LISN
Meta-analysis 9 studies of 228 patients
15% ipsilateral, 9% contralateral carcinoma
Ipsilateral 3x more likely than contralateral
• A “model of premalignancy for ALH intermediate between a local precursor and a generalised risk for both breasts”
Page DL. Lancet. 2003;361:125-9
![Page 18: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/18.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
Is there a sub-group of pre-invasive LCIS? LCIS with Microinvasion
6 LCIS with microinvasion described
Nemoto T et al. J Surg Oncol 1998; 67; 41-46
![Page 19: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/19.jpg)
Case 19
![Page 20: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/20.jpg)
![Page 21: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/21.jpg)
![Page 22: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/22.jpg)
![Page 23: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/23.jpg)
![Page 24: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/24.jpg)
![Page 25: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/25.jpg)
![Page 26: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/26.jpg)
![Page 27: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/27.jpg)
![Page 28: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/28.jpg)
![Page 29: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/29.jpg)
![Page 30: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/30.jpg)
Diagnosis - Fibrocystic change with
papillomas and florid usual epithelial hyperplasia
![Page 31: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/31.jpg)
Case 32
![Page 32: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/32.jpg)
![Page 33: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/33.jpg)
![Page 34: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/34.jpg)
![Page 35: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/35.jpg)
![Page 36: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/36.jpg)
![Page 37: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/37.jpg)
![Page 38: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/38.jpg)
![Page 39: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/39.jpg)
![Page 40: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/40.jpg)
![Page 41: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/41.jpg)
![Page 42: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/42.jpg)
![Page 43: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/43.jpg)
![Page 44: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/44.jpg)
![Page 45: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/45.jpg)
![Page 46: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/46.jpg)
Diagnosis - Fibrocystic change with
atypical lobular hyperplasia and flat high grade DCIS
![Page 47: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/47.jpg)
Case 54
![Page 48: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/48.jpg)
![Page 49: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/49.jpg)
![Page 50: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/50.jpg)
![Page 51: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/51.jpg)
![Page 52: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/52.jpg)
![Page 53: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/53.jpg)
![Page 54: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/54.jpg)
Diagnosis - Radial scar with florid usual
epithelial hyperplasia
![Page 55: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/55.jpg)
• Central fibro-elastosis with entrapped tubular structures
• Usual epithelial hyperplasia
• Helpful features – retraction around tubular structures – often seen in radial scars
• Lack of fibroblastic stromal reaction (commonly, but not invariably seen (!) in tubular carcinoma)
• Confirm presence of myoepithelial cells and exclude diagnosis of tubular carcinoma (e.g. with smooth muscle myosin or smooth muscle actin or p63)
• In the epithelial proliferation look for (a) mixed population, (b) streaming and (c) slit-like peripheral spaces
Radial Scar
![Page 56: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/56.jpg)
![Page 57: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/57.jpg)
![Page 58: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/58.jpg)
![Page 59: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/59.jpg)
![Page 60: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/60.jpg)
![Page 61: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/61.jpg)
![Page 62: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/62.jpg)
Case 44
![Page 63: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/63.jpg)
![Page 64: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/64.jpg)
![Page 65: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/65.jpg)
![Page 66: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/66.jpg)
![Page 67: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/67.jpg)
![Page 68: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/68.jpg)
![Page 69: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/69.jpg)
Diagnosis - High grade DCIS with comedo-
type necrosis and cancerisation of lobules.
No invasion or microinvasion.
![Page 70: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/70.jpg)
MicroinvasionMicroinvasion• DCIS with a focus of invasion less than 1mm in
max. dimension• More than one focus, if each less than 1mm
Individual deposits may vary in size from a few islands to 1 mm diameter
• In the non-specialised, interlobular or inter-ductal connective tissue - neoplastic islands definitely within interlobular fibrous or adipose tissue
Excludes:Ultrastructural or immunocytochemical evidence of
breached or discontinuous basement membrane"Cancerisation of lobules"
![Page 71: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/71.jpg)
Microinvasion
Observations
• Associated with high-grade comedo DCIS more than other types
• Increasing risk of axillary node involvement with increasing duct space involvement (>50 ducts)
![Page 72: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/72.jpg)
Microinvasion
Problems of interpretation
• Duct boundary poorly defined
• Periductal fibrosis
• Indistinct basement membrane zone
• Tangential cutting of involved duct/lobule
![Page 73: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/73.jpg)
Microinvasion
Tips
• Outside organoid structures
• Involves non-specialised stroma
• Host lymphocytic response
• No myoepithelial component
![Page 74: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/74.jpg)
Microinvasion
Key points
• Restrictive definition
• Rare
• Axillary node involvement low
• Prognosis very good
![Page 75: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/75.jpg)
![Page 76: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/76.jpg)
![Page 77: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/77.jpg)
![Page 78: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/78.jpg)
![Page 79: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/79.jpg)
Case 11a
![Page 80: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/80.jpg)
![Page 81: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/81.jpg)
![Page 82: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/82.jpg)
![Page 83: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/83.jpg)
![Page 84: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/84.jpg)
![Page 85: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/85.jpg)
![Page 86: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/86.jpg)
![Page 87: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/87.jpg)
![Page 88: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/88.jpg)
![Page 89: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/89.jpg)
Diagnosis -Medullary-like carcinoma
![Page 90: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/90.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
CASE ?
• 36 year old patient
• Mastectomy and ALND post chemotherapy
• 5 months previously had core from 41mm mobile hypoechoic mobile mass in RUOQ
![Page 91: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/91.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 92: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/92.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 93: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/93.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
Core Biopsy• B5, invasive carcinoma of provisional (core)
grade 3 (333) and no special type
• ER = 6/8
• PGR = 0/8
• HER2 = negative (score 0)
![Page 94: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/94.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 95: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/95.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 96: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/96.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 97: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/97.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 98: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/98.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 99: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/99.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 100: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/100.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 101: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/101.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 102: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/102.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 103: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/103.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 104: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/104.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 105: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/105.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
Diagnosis
Residual carcinoma cells mimicking histiocytes
![Page 106: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/106.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
• Central fibrotic scarring usually seen
• Patchy chronic inflammation within and around fibrosis
• Oedema or mucinous or myxoid changes to stroma or even areas of necrosis
• Cancer cells may mimic histiocytes, and vice versa, but collections of macrophages may also be present
• Cytokeratin IHC invaluable
Post-Chemotherapy Changes
![Page 107: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/107.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 108: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/108.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 109: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/109.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 110: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/110.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
Grade 1 Some alteration to individual cells but no overall reduction in numbers compared to pre-treatment core
Grade 2 Mild loss of invasive cells, still high cellularityGrade 3 Considerable reduction, up to 90% lossGrade 4 Marked reduction - only small clusters of
widely dispersed cells detectedGrade 5 No invasive carcinoma, in situ carcinoma or
tumour stroma may still be noted
Bonadonna G et al. J Natl Cancer Inst. 1990 3;82:1539-45Smith IC et al. J Clin Oncol 2002;20:1456-66
Response to Chemotherapy
![Page 111: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/111.jpg)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
Response to Chemotherapy
1. Disappearance of all tumour
2. Presence of in situ carcinoma but no residual invasive tumour & no metastatic carcinoma found in the lymph nodes
3. Invasive carcinoma present with stromal changes, such as sclerosis or fibrosis
4. Few modifications of appearance of tumour
Chevallier B et al. Am J Clin Oncol 1993;16:223–228
![Page 112: Session 5](https://reader035.vdocuments.mx/reader035/viewer/2022070413/56814cec550346895db9eae5/html5/thumbnails/112.jpg)